Cost-effectiveness analysis of telephone cognitive-behaviour therapy for adolescents with obsessive-compulsive disorder.

Obsessive-compulsive disorder adolescent cognitive behavioural therapies cost-effectiveness economic evaluation

Journal

BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931

Informations de publication

Date de publication:
Jan 2019
Historique:
entrez: 15 2 2019
pubmed: 15 2 2019
medline: 15 2 2019
Statut: ppublish

Résumé

Telephone cognitive-behaviour therapy (TCBT) may be a cost-effective method for improving access to evidence-based treatment for obsessive-compulsive disorder (OCD) in young people.AimsEconomic evaluation of TCBT compared with face-to-face CBT for OCD in young people. Randomised non-inferiority trial comparing TCBT with face-to-face CBT for 72 young people (aged 11 to 18) with a diagnosis of OCD. Cost-effectiveness at 12-month follow-up was explored in terms of the primary clinical outcome (Children's Yale-Brown Obsessive-Compulsive Scale, CY-BOCS) and quality-adjusted life-years (QALYs) (trial registration: ISRCTN27070832). Total health and social care costs were higher for face-to-face CBT (mean total cost £2965, s.d. = £1548) than TCBT (mean total cost £2475, s.d. = £1024) but this difference was non-significant (P = 0.118). There were no significant between-group differences in QALYs or the CY-BOCS and there was strong evidence to support the clinical non-inferiority of TCBT. Cost-effectiveness analysis suggests a 74% probability that face-to-face CBT is cost-effective compared with TCBT in terms of QALYs, but the result was less clear in terms of CY-BOCS, with TCBT being the preferred option at low levels of willingness to pay and the probability of either intervention being cost-effective at higher levels of willingness to pay being around 50%. Although cost-effectiveness of TCBT was sensitive to the outcome measure used, TCBT should be considered a clinically non-inferior alternative when access to standard clinic-based CBT is limited, or when patient preference is expressed.Declaration of interestD.M.-C. reports research grants from the Swedish Research Council (Vetenskapsrådet), the Swedish Research Council for Health, working life and welfare (Forte), the US National Institute of Mental Health (NIMH), the UK National Institute of Health Research (NIHR), as well as royalties from Wolters Kluwer Health and Elsevier, all unrelated to the submitted work.

Sections du résumé

BACKGROUND BACKGROUND
Telephone cognitive-behaviour therapy (TCBT) may be a cost-effective method for improving access to evidence-based treatment for obsessive-compulsive disorder (OCD) in young people.AimsEconomic evaluation of TCBT compared with face-to-face CBT for OCD in young people.
METHOD METHODS
Randomised non-inferiority trial comparing TCBT with face-to-face CBT for 72 young people (aged 11 to 18) with a diagnosis of OCD. Cost-effectiveness at 12-month follow-up was explored in terms of the primary clinical outcome (Children's Yale-Brown Obsessive-Compulsive Scale, CY-BOCS) and quality-adjusted life-years (QALYs) (trial registration: ISRCTN27070832).
RESULTS RESULTS
Total health and social care costs were higher for face-to-face CBT (mean total cost £2965, s.d. = £1548) than TCBT (mean total cost £2475, s.d. = £1024) but this difference was non-significant (P = 0.118). There were no significant between-group differences in QALYs or the CY-BOCS and there was strong evidence to support the clinical non-inferiority of TCBT. Cost-effectiveness analysis suggests a 74% probability that face-to-face CBT is cost-effective compared with TCBT in terms of QALYs, but the result was less clear in terms of CY-BOCS, with TCBT being the preferred option at low levels of willingness to pay and the probability of either intervention being cost-effective at higher levels of willingness to pay being around 50%.
CONCLUSIONS CONCLUSIONS
Although cost-effectiveness of TCBT was sensitive to the outcome measure used, TCBT should be considered a clinically non-inferior alternative when access to standard clinic-based CBT is limited, or when patient preference is expressed.Declaration of interestD.M.-C. reports research grants from the Swedish Research Council (Vetenskapsrådet), the Swedish Research Council for Health, working life and welfare (Forte), the US National Institute of Mental Health (NIMH), the UK National Institute of Health Research (NIHR), as well as royalties from Wolters Kluwer Health and Elsevier, all unrelated to the submitted work.

Identifiants

pubmed: 30762502
pii: S205647241800073X
doi: 10.1192/bjo.2018.73
pmc: PMC6343121
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e7

Subventions

Organisme : Medical Research Council
ID : MR/N001400/1
Pays : United Kingdom

Références

Br J Psychiatry. 2007 Dec;191:521-7
pubmed: 18055956
Med Interface. 1995 Apr;8(4):102-9
pubmed: 10141765
World Psychiatry. 2016 Feb;15(1):80-1
pubmed: 26833615
BMJ. 2006 Apr 29;332(7548):1030-2
pubmed: 16644834
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004856
pubmed: 17054218
BMJ. 2006 Oct 28;333(7574):883
pubmed: 16935946
Behav Cogn Psychother. 2009 Jul;37(4):469-74
pubmed: 19545482
J Child Psychol Psychiatry. 2008 May;49(5):489-98
pubmed: 18400058
J Am Acad Child Adolesc Psychiatry. 2008 May;47(5):593-602
pubmed: 18356758
J Am Acad Child Adolesc Psychiatry. 2014 Dec;53(12):1298-1307.e2
pubmed: 25457928
PLoS One. 2012;7(9):e42916
pubmed: 23028436
Child Adolesc Ment Health. 2005 Sep;10(3):143-144
pubmed: 32806851
Health Econ. 1998 Dec;7(8):723-40
pubmed: 9890333
Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S68-80
pubmed: 9566468
BMJ Open. 2017 May 17;7(5):e015246
pubmed: 28515196
Health Econ. 2001 Mar;10(2):179-84
pubmed: 11252048
Health Technol Assess. 2006 Sep;10(33):iii, xi-xiv, 1-168
pubmed: 16959169
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Br J Psychiatry. 2005 Aug;187:106-8
pubmed: 16055820
Cogn Behav Ther. 2003;32(1):13-25
pubmed: 16291531
Eur Psychiatry. 2006 Mar;21(2):75-80
pubmed: 16360307
Acta Psychiatr Scand. 2008 Jan;117(1):57-66
pubmed: 18005369
Health Econ. 2013 Jan;22(1):22-34
pubmed: 22109960
Br J Psychiatry. 2007 Nov;191:436-40
pubmed: 17978324
Br J Psychiatry. 2001 Oct;179:324-9
pubmed: 11581112
J Child Adolesc Psychopharmacol. 2003;13 Suppl 1:S61-9
pubmed: 12880501
J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):844-52
pubmed: 9183141
J Ment Health. 2013 Apr;22(2):101-10
pubmed: 23574502
Br J Psychiatry. 2014 Jan;204(1):77-8
pubmed: 24262813
Behav Res Ther. 2009 Nov;47(11):910-20
pubmed: 19647230

Auteurs

Hiong Tie (H)

Research Worker,Health Service and Population Research Department,Institute of Psychiatry, Psychology and Neuroscience at King's College London,UK.

Georgina Krebs (G)

Clinical Research Training Fellow,Social, Genetic and Developmental Psychiatry Centre Institute of Psychiatry, Psychology and Neuroscience at King's College London,UK.

Katie Lang (K)

Trainee Clinical Psychologist,Department of Psychology,Institute of Psychiatry, Psychology and Neuroscience at King's College London,UK.

James Shearer (J)

Lecturer in Health Economics,Health Service and Population Research Department,Institute of Psychiatry, Psychology and Neuroscience at King's College London,UK.

Cynthia Turner (C)

Research Fellow,Primary Care Clinical Unit,University of Queensland,Australia.

David Mataix-Cols (D)

Professor of Child and Adolescent Psychiatric Science,Department of Clinical Neuroscience Karolinska Institutet,Sweden.

Karina Lovell (K)

Professor of Mental Health,Division of Nursing, Midwifery and Social Work, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust,UK.

Isobel Heyman (I)

Consultant Child and Adolescent Psychiatrist,Great Ormond Street Hospital for Children,UK.

Sarah Byford (S)

Professor of Health Economics,Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience at King's College London,UK.

Classifications MeSH